Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 145

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 145
---
U. S. residents, in accordance with the applicable provisions of the U. S. Internal Revenue Code of 1986, as amended, or the Code.

Awards granted under our plans may be subject to vesting schedules.
Options to purchase our ordinary shares granted under our plans expire 10 years from the grant date. The plans address the treatment of
vested and unvested awards upon the termination of employment of the award holder as well as upon consummation of a merger or consolidation
of our company, or sale of all or substantially all of our shares or assets.

Subsidiary Equity Incentive
Plans

In addition to the share option and incentive plans at our parent
company level, each of our subsidiaries has adopted its own equity incentive plan. The following table presents information regarding
our subsidiaries’ equity incentive plans, including the percentage of the equity of those companies that may be issued or granted
as equity incentives to employees, directors or service providers of those companies and the percentage of that equity that has been issued
or granted as of March 17, 2025 (in both cases, after including shares underlying options).

  Subsidiary      Percentage of Subsidiary's Equity Issuable as Equity Incentives      Percentage of Equity Granted as of March 17, 2025  
  Subsidiary      Percentage of Subsidiary's Equity Issuable as Equity Incentives                                   as Equity Incentives  
                                                                                       Percentage of Equity Granted as of March 17, 2025  
                                                                                                                    as Equity Incentives  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  AgPlenus                                                                   13.8                                                    8.9  
  Biomica                                                                      12                                                   7.62  
  Casterra                                                                    7.5                                                    3.9  
  Lavie Bio                                                                  10.5                                                    8.8  

Grants under our subsidiaries’ equity incentive plans may
qualify for favorable treatment under the tax law provisions of the United States or Israel.

The share-based payments under our subsidiary equity incentive plans are presented as
non-controlling interests in the financial statements and were valued at approximately $1.4 million in 2024, as detailed in Note 17g to
the financial statements included in this Annual Report under Item 18.

85

C. Board
Practices

Board of Directors

Under the Companies Law and our articles of association, the supervision